Diazyme has received an FDA emergency use authorization (EUA) for the Diazyme DZ-Lite SARS-CoV-2 IgM CLIA test. The Diazyme IgM covid-19 antibody test runs on the fully automated DZ-Lite 3000 Plus chemiluminescence analyzer. “Diazyme continues to serve during the public health emergency with innovative products in covid-19 serology (antibody) testing,” says Chong Yuan, PhD, managing director of Diazyme Laboratories. “The IgM test is typically used together with the IgG test for a more complete serology profile. The Diazyme DZ-Lite SARS-CoV-2 IgM test is highly sensitive and specific and does not cross-react when tested with an extensive list of interferents, including no cross reactivity to the common HKU1, OC43, NL63, 229E coronavirus strains. Recent independent performance studies in peer-reviewed journals cite excellent results with Diazyme serology tests.” For more information, visit Diazyme Laboratories.
December 13, 2021
Longhorn Vaccines and Diagnostics Encouraged by FDA to Help Solve Coronavirus Testing Bottleneck by Teaming PrimeStore MTM with Diagnostic Developers
March 3, 2020
October 22, 2020